

SWIXX AND JAZZ EXPAND PARTNERSHIP

SWIXX ANNOUNCEMENT NO. 47

April 19th, 2022

Baar, Switzerland – Swixx BioPharma AG of Baar, Switzerland, announced today the extension of its collaboration with Jazz Pharmaceuticals Ireland Limited of Dublin, a fully-owned subsidiary of Jazz Pharmaceuticals plc. In March 2021, Jazz appointed Swixx as exclusive distributor to import, use, market, sell and distribute Defitelio[®] (defibrotide) in Estonia, Latvia and Lithuania. With the agreed amendment, and as of April 14th, the territory for Defitelio[®] is extended to the countries of Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovenia and Slovakia.

Defitelio[®] (defibrotide) is indicated in the EU for the treatment of severe hepatic veno-occlusive disease also known as sinusoidal obstruction syndrome in hematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children, and infants over 1 month of age.¹

“We are delighted to strengthen our partnership with Jazz Pharmaceuticals by expanding our distribution of Defitelio[®] in additional geographies.” commented Swixx COO, Dr. Dezso Martha. “By capitalizing on our strong presence across CEE geographies, we will be working in collaboration with Jazz and the broad CEE healthcare community to support the availability of Defitelio[®] for CEE patients.”

About Swixx BioPharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, Russia and several Eurasian Economic Union countries plus Uzbekistan. With over 1000 employees and sales likely to exceed 600M Euros in 2022, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Vedrana Sokac Brataljenovic, Public Affairs Director, Swixx BioPharma AG
vedrana.sokac@swixxbiopharma.com Tel: +385 1 425 6086

¹Defitelio 80 mg/mL concentrate for solution for infusion Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/defitelio-epar-product-information_en.pdf